{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:59:20Z","timestamp":1696323560079},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"DOI":"10.2146\/ajhp110164","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T02:46:29Z","timestamp":1332470789000},"page":"583-586","source":"Crossref","is-referenced-by-count":6,"title":["Probable rifaximin-induced neutropenia"],"prefix":"10.1093","volume":"69","author":[{"given":"Lauren M.","family":"Hynicka","sequence":"first","affiliation":[{"name":"University of Maryland School of Pharmacy, Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathyrn N.","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland Medical Center, Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607004673000_b1-0690583","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. http:\/\/hcupnet.ahrq.gov (accessed 2010 May 6)."},{"key":"2019041607004673000_b2-0690583","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJM199708143370707","article-title":"Treatment of hepatic encephalopathy","volume":"337","author":"Riordan","year":"1997","journal-title":"N Engl J Med"},{"key":"2019041607004673000_b3-0690583","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","article-title":"Rifaximin: a review of its use in the management of traveller\u2019s diarrhoea","volume":"65","author":"Robins","year":"2005","journal-title":"Drugs"},{"key":"2019041607004673000_b4-0690583","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041607004673000_b5-0690583","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1128\/AAC.45.5.1572-1577.2001","article-title":"Tolerance and pharmacokinetic interactions of rifabutin and azithromycin","volume":"45","author":"Hafner","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607004673000_b6-0690583","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"2019041607004673000_b7-0690583","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1067\/mcp.2003.3","article-title":"Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin","volume":"73","author":"Hamzeh","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2019041607004673000_b8-0690583","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1592\/phco.21.5.493.34488","article-title":"Idiosyncratic rifabutin-induced leukopenia and SIADH: case report and review","volume":"21","author":"Chitre","year":"2001","journal-title":"Pharmacotherapy"},{"key":"2019041607004673000_b9-0690583","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2019041607004673000_b10-0690583","first-page":"251","article-title":"Leucopenia caused by two rifampicin preparations","volume":"65","author":"Van Assendelft","year":"1984","journal-title":"Eur J Respir Dis"},{"key":"2019041607004673000_b11-0690583","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(05)65109-4","article-title":"Severe neutropenia caused by recommended prophylactic doses of rifabutin","volume":"348","author":"Apseloff","year":"1996","journal-title":"Lancet"},{"key":"2019041607004673000_b12-0690583","volume-title":"Xifaxan (rifaximin) product information","year":"2010"},{"key":"2019041607004673000_b13-0690583","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers","volume":"14","author":"Descombe","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"2019041607004673000_b14-0690583","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002280050426","article-title":"Rifaximin systemic absorption in patients with ulcerative colitis","volume":"54","author":"Rizzello","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2019041607004673000_b15-0690583","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1023\/A:1026648812439","article-title":"Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial","volume":"44","author":"Gionchetti","year":"1999","journal-title":"Dig Dis Sci"},{"key":"2019041607004673000_b16-0690583","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2036.1999.00553.x","article-title":"Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis","volume":"13","author":"Gionchetti","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"2019041607004673000_b17-0690583","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","article-title":"Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts","volume":"34","author":"Chalasani","year":"2001","journal-title":"Hepatology"},{"key":"2019041607004673000_b18-0690583","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.34.8.1081","article-title":"Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience","volume":"34","author":"Connell","year":"1993","journal-title":"Gut"},{"key":"2019041607004673000_b19-0690583","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/7\/583\/28455630\/ajhp0583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T07:02:35Z","timestamp":1555398155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/7\/583\/5112134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110164","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,1]]},"published":{"date-parts":[[2012,4,1]]}}}